CervoMed Inc. Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
CervoMed Inc. (CRVO) reported Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-24.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill · last filed 2023-03-24
- CervoMed Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- CervoMed Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- CervoMed Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2021-12-31 was $8.60M.
- CervoMed Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2021-09-30 was $8.64M.
- CervoMed Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- CervoMed Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2021 was $8.64M.
- CervoMed Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2020 was $0.00.
| Period end | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 3 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 6 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 9 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $0.00 derived: sum of 2 quarters · filed 2023-03-24 | $0.00 10-K · filed 2023-03-24 | |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 | ||
| 2021-12-31 | $8.60M 10-K · filed 2022-03-18 | $17.24M derived: sum of 2 quarters · filed 2022-11-14 | $8.64M 10-K · filed 2023-03-24 | |
| 2021-09-30 | $8.64M 10-Q · filed 2022-11-14 | $8.64M 10-Q · filed 2022-11-14 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $0.00 derived: sum of 2 quarters · filed 2022-03-18 | $0.00 10-K · filed 2022-03-18 | |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |